chrX-101354636-A-G
Variant summary
Our verdict is Pathogenic. Variant got 10 ACMG points: 10P and 0B. PM1PM2PP2PP3_StrongPP5
The ENST00000308731.8(BTK):c.1625T>C(p.Leu542Pro) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Synonymous variant affecting the same amino acid position (i.e. L542L) has been classified as Likely benign.
Frequency
Consequence
ENST00000308731.8 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 10 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
BTK | NM_000061.3 | c.1625T>C | p.Leu542Pro | missense_variant | 16/19 | ENST00000308731.8 | NP_000052.1 | |
BTK | NM_001287344.2 | c.1727T>C | p.Leu576Pro | missense_variant | 16/19 | NP_001274273.1 | ||
BTK | NM_001287345.2 | c.1097T>C | p.Leu366Pro | missense_variant | 14/17 | NP_001274274.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
BTK | ENST00000308731.8 | c.1625T>C | p.Leu542Pro | missense_variant | 16/19 | 1 | NM_000061.3 | ENSP00000308176 | P3 |
Frequencies
GnomAD3 genomes Cov.: 22
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 22
ClinVar
Submissions by phenotype
X-linked agammaglobulinemia with growth hormone deficiency Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 22, 2024 | This sequence change replaces leucine, which is neutral and non-polar, with proline, which is neutral and non-polar, at codon 542 of the BTK protein (p.Leu542Pro). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with X-linked agammaglobulinemia (PMID: 7849697, 12655572). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 11381). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt BTK protein function with a positive predictive value of 80%. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Oct 01, 1994 | - - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Nov 03, 2019 | The BTK c.1625T>C; p.Leu542Pro variant (rs128621203) is reported in the literature in individuals affected with X-linked agammaglobulinemia (Conley 1994, Danielian 2003). This variant is reported in ClinVar (Variation ID: 11381), and is absent from general population databases (Exome Variant Server, Genome Aggregation Database), indicating it is not a common polymorphism. The leucine at codon 542 is highly conserved, and computational analyses (SIFT, PolyPhen-2) predict that this variant is deleterious. Structural analyses of the BTK protein show that leucine 542 may be important for substrate binding (Mattsson 1996). However, given the limited amount of clinical data and lack of functional data, the significance of the p.Leu542Pro variant is uncertain at this time. References: Conley et al. Screening of genomic DNA to identify mutations in the gene for Bruton's tyrosine kinase. Hum Mol Genet. 1994 Oct;3(10):1751-6. Danielian S et al. Bruton tyrosine kinase gene mutations in Argentina. Hum Mutat. 2003 Apr;21(4):451. Mattsson PT et al. X-linked agammaglobulinemia (XLA): a genetic tyrosine kinase (Btk) disease. Bioessays. 1996 Oct;18(10):825-34. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at